ARM, EFPIA and EuropaBio Call for Advanced Therapies to be Exempt from EU GMO Legislation
Alliance for Regenerative Medicine, European Federation of Pharmaceutical Industries and Associations, and European Association for Bioindustries Call for
Advanced Therapies
needs
patients
, 2021
The European Commission should exempt advanced therapies from Genetically Modified Organism (GMO) legislation, which hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines, said the Alliance for Regenerative Medicine (ARM), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the European Association of Bioindustries (EuropaBio) in a paper published online yesterday in the journal
Human Gene Therapy.
The Alliance for Regenerative Medicine: ARM, EFPIA and EuropaBio Call for Advanced Therapies to be Exempt from EU GMO Legislation
Advanced Therapies
needs
patients
, 2021
Human Gene Therapy.
The European Commission recognized that GMO requirements hinder the conduct of clinical trials in its April 29 study on new genomic techniques and in the 2020 Pharmaceutical Strategy for Europe, when it called for GMO legislation to be fit for purpose for addressing medicines. The original GMO legislation was primarily enacted to protect food consumers and the environment, but Advanced Therapy Medicinal Products (ATMPs) such as gene therapies are affected as an unintended consequence. The uneven application of GMO requirements across EU Member States causes significant clinical trial delays despite findings that gene therapies pose a negligible risk to the environment.
Pharma, comms and patient group leaders join judging panel for Patient Partnership Index 2021
11th March 2021
Senior leaders from UK and European pharma have come together to judge the Patient Partnership Index 2021. Now in its second year, the Index provides companies in the pharmaceutical and biotech industry the opportunity to showcase partnerships with patient organisations in communications and advocacy over the past year, including those in response to the COVID-19 pandemic.
This year, the Index has opened to above country campaigns, allowing projects from around the world to celebrate their impact and share their insights. Entries are awarded GOLD, SILVER and FINALIST standards by the judging panel, against a metric developed by healthcare specialist communications agency and co-creators of the Index, OVID Health.